Pathogenic potential of interferon αβ in acute influenza infection

Influenza symptoms vary from mild disease to death; however, determinants of severity are unclear. Type I interferons (IFNαβ) are recognized as key antiviral cytokines. Here we show that, surprisingly, influenza-infected 129 mice have increased lung damage, morbidity and mortality, yet higher levels of IFNαβ, than C57BL/6 mice. Consistently, IFNα treatment of influenza-infected C57BL/6 mice increases morbidity. IFNαβ receptor deficiency in 129 mice decreases morbidity, lung damage, proinflammatory cytokines and lung-infiltrating inflammatory cells, and reduces expression of the death-inducing receptor DR5 on lung epithelia and its ligand TRAIL on inflammatory monocytes. Depletion of PDCA-1+ cells or interruption of TRAIL-DR5 interaction protects infected 129 mice. Selective lack of IFNαβ signalling in stromal cells abolishes epithelial DR5 upregulation and apoptosis, reducing host susceptibility. Hence, excessive IFNαβ signalling in response to acute influenza infection can result in uncontrolled inflammation and TRAIL-DR5-mediated epithelial cell death, which may explain morbidity and has important implications for treatment of severe disease.

[1]  T. Tumpey,et al.  Highly Pathogenic Avian Influenza H5N1 Viruses Elicit an Attenuated Type I Interferon Response in Polarized Human Bronchial Epithelial Cells , 2007, Journal of Virology.

[2]  M. Kruhlak,et al.  Differential expression of IFN-alpha and TRAIL/DR5 in lymphoid tissue of progressor versus nonprogressor HIV-1-infected patients. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[3]  P. D. de Bakker,et al.  Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. , 2011, The Journal of clinical investigation.

[4]  J. Cummins,et al.  Protection from lethal influenza virus challenge by oral type 1 interferon. , 2007, Biochemical and biophysical research communications.

[5]  Y. Matsuoka,et al.  Early Control of H5N1 Influenza Virus Replication by the Type I Interferon Response in Mice , 2009, Journal of Virology.

[6]  Robert W. Williams,et al.  Host Genetic Variation Affects Resistance to Infection with a Highly Pathogenic H5N1 Influenza A Virus in Mice , 2009, Journal of Virology.

[7]  Paul Kellam,et al.  IFITM3 restricts the morbidity and mortality associated with influenza , 2012, Nature.

[8]  David E. Swayne,et al.  Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus , 2006, Nature.

[9]  M. Weijerman,et al.  Increased Pro-inflammatory Cytokine Production in Down syndrome Children Upon Stimulation with Live Influenza A Virus , 2012, Journal of Clinical Immunology.

[10]  Y. Guan,et al.  Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? , 2002, The Lancet.

[11]  Yi Guan,et al.  Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia , 2006, Nature Medicine.

[12]  G. Kochs,et al.  The Viral Nucleoprotein Determines Mx Sensitivity of Influenza A Viruses , 2011, Journal of Virology.

[13]  T. Brodnicki,et al.  The Size of the Plasmacytoid Dendritic Cell Compartment Is a Multigenic Trait Dominated by a Locus on Mouse Chromosome 7 , 2012, The Journal of Immunology.

[14]  A. Shahangian,et al.  Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. , 2009, The Journal of clinical investigation.

[15]  Pedro Romero,et al.  Type I interferon inhibits interleukin-1 production and inflammasome activation. , 2011, Immunity.

[16]  A. Sher,et al.  Intranasal Poly-IC treatment exacerbates tuberculosis in mice through the pulmonary recruitment of a pathogen-permissive monocyte/macrophage population. , 2010, The Journal of clinical investigation.

[17]  B. Aronow,et al.  Blockade of Chronic Type I Interferon Signaling to Control Persistent LCMV Infection , 2013, Science.

[18]  P. Palese,et al.  Seroevidence for H5N1 Influenza Infections in Humans: Meta-Analysis , 2012, Science.

[19]  John Steel,et al.  Influenza A Virus Strains Differ in Sensitivity to the Antiviral Action of Mx-GTPase , 2008, Journal of Virology.

[20]  G. Kochs,et al.  Intranasal Administration of Alpha Interferon Reduces Seasonal Influenza A Virus Morbidity in Ferrets , 2009, Journal of Virology.

[21]  M. Albert,et al.  Type I and Type III Interferons Drive Redundant Amplification Loops to Induce a Transcriptional Signature in Influenza-Infected Airway Epithelia , 2013, PLoS pathogens.

[22]  M. Katze,et al.  Molecular Signatures Associated with Mx1-Mediated Resistance to Highly Pathogenic Influenza Virus Infection: Mechanisms of Survival , 2011, Journal of Virology.

[23]  J. Peiris,et al.  Innate immune responses to influenza A H5N1: friend or foe? , 2009, Trends in immunology.

[24]  Matthias Mack,et al.  Lung epithelial apoptosis in influenza virus pneumonia: the role of macrophage-expressed TNF-related apoptosis-inducing ligand , 2008, The Journal of experimental medicine.

[25]  Nan Yan,et al.  Intrinsic antiviral immunity , 2012, Nature Immunology.

[26]  Carole R. Baskin,et al.  Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus , 2009, Proceedings of the National Academy of Sciences.

[27]  Klaus Schughart,et al.  Host Genetic Background Strongly Influences the Response to Influenza A Virus Infections , 2009, PloS one.

[28]  M Aguet,et al.  Functional role of type I and type II interferons in antiviral defense. , 1994, Science.

[29]  G. Jackson,et al.  Evidence for a heritable predisposition to death due to influenza. , 2008, The Journal of infectious diseases.

[30]  A. García-Sastre,et al.  Type I IFN Modulates Innate and Specific Antiviral Immunity1 , 2000, The Journal of Immunology.

[31]  O. Haller,et al.  Interferon induces a unique protein in mouse cells bearing a gene for resistance to influenza virus. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[32]  O. Haller,et al.  Enhanced virus resistance of transgenic mice expressing the human MxA protein , 1995, Journal of virology.

[33]  G. Kochs,et al.  Protective Role of Beta Interferon in Host Defense against Influenza A Virus , 2006, Journal of Virology.

[34]  S. Brody,et al.  Growth and differentiation of mouse tracheal epithelial cells: selection of a proliferative population. , 2002, American journal of physiology. Lung cellular and molecular physiology.

[35]  C. Epstein,et al.  Enhanced sensitivity of trisomy 21 monocytes to the maturation-inhibiting effect ot interferon. , 1980, Cellular immunology.

[36]  H. Walczak,et al.  TRAIL: a multifunctional cytokine. , 2007, Frontiers in bioscience : a journal and virtual library.

[37]  Christine A. Biron,et al.  Type 1 Interferons and the Virus-Host Relationship: A Lesson in Détente , 2006, Science.

[38]  G. Trinchieri,et al.  Mouse Strain Differences in Plasmacytoid Dendritic Cell Frequency and Function Revealed by a Novel Monoclonal Antibody , 2003, The Journal of Immunology.

[39]  M. Horisberger,et al.  Interferons, Mx genes, and resistance to influenza virus. , 1995, American journal of respiratory and critical care medicine.

[40]  A. Da'dara,et al.  Type I Interferons Increase Host Susceptibility to Trypanosoma cruzi Infection , 2011, Infection and Immunity.

[41]  Ryan M. O’Connell,et al.  Type I Interferon Production Enhances Susceptibility to Listeria monocytogenes Infection , 2004, The Journal of experimental medicine.

[42]  Akiko Iwasaki,et al.  Inflammasomes as mediators of immunity against influenza virus. , 2011, Trends in immunology.

[43]  H. Lopez-Gatell,et al.  Pandemic (H1N1) 2009 Virus and Down Syndrome Patients , 2010, Emerging infectious diseases.

[44]  D. Graham,et al.  HIV turns plasmacytoid dendritic cells (pDC) into TRAIL-expressing killer pDC and down-regulates HIV coreceptors by Toll-like receptor 7-induced IFN-α , 2007, Proceedings of the National Academy of Sciences.

[45]  Judith N. Mandl,et al.  Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections , 2008, Nature Medicine.

[46]  Christina Falschlehner,et al.  TRAIL and other TRAIL receptor agonists as novel cancer therapeutics. , 2009, Advances in experimental medicine and biology.

[47]  Courtney R. Plumlee,et al.  Inteferons pen the JAK-STAT pathway. , 2008, Seminars in cell & developmental biology.

[48]  J. Lifson,et al.  CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon-dependent, TRAIL/DR5-mediated apoptosis. , 2005, Blood.

[49]  C. Benedict,et al.  TRAIL: not just for tumors anymore? , 2012, The Journal of experimental medicine.

[50]  D. Moskophidis,et al.  The Role of Alpha/Beta and Gamma Interferons in Development of Immunity to Influenza A Virus in Mice , 2000, Journal of Virology.

[51]  R. Schreiber,et al.  Persistent LCMV Infection Is Controlled by Blockade of Type I Interferon Signaling , 2013, Science.

[52]  P. Horby,et al.  The Role of Host Genetics in Susceptibility to Influenza: A Systematic Review , 2012, PloS one.

[53]  G. Trinchieri,et al.  Plasmacytoid dendritic cells in immunity , 2004, Nature Immunology.

[54]  S. Günther,et al.  Lambda Interferon Renders Epithelial Cells of the Respiratory and Gastrointestinal Tracts Resistant to Viral Infections , 2010, Journal of Virology.

[55]  R. Balderas,et al.  Loss of memory B cells during chronic HIV infection is driven by Foxo3a- and TRAIL-mediated apoptosis. , 2011, The Journal of clinical investigation.

[56]  J. Renauld,et al.  Interferon-λ Contributes to Innate Immunity of Mice against Influenza A Virus but Not against Hepatotropic Viruses , 2008, PLoS pathogens.

[57]  Yan Li,et al.  Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus , 2007, Nature.

[58]  A. García-Sastre,et al.  The Role of Interferon in Influenza Virus Tissue Tropism , 1998, Journal of Virology.

[59]  G. Trinchieri,et al.  Type I interferon: friend or foe? , 2010, The Journal of experimental medicine.

[60]  T. Uyeki,et al.  Epidemiology of cases of H5N1 virus infection in Indonesia, July 2005-June 2006. , 2007, The Journal of infectious diseases.

[61]  W. Seeger,et al.  Macrophage-expressed IFN-β Contributes to Apoptotic Alveolar Epithelial Cell Injury in Severe Influenza Virus Pneumonia , 2013, PLoS pathogens.

[62]  F. Barré-Sinoussi,et al.  Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. , 2009, The Journal of clinical investigation.

[63]  Robert Peach,et al.  Endothelial Cells Are Central Orchestrators of Cytokine Amplification during Influenza Virus Infection , 2011, Cell.

[64]  K. Legge,et al.  Plasmacytoid Dendritic Cells Enhance Mortality during Lethal Influenza Infections by Eliminating Virus-Specific CD8 T Cells , 2010, The Journal of Immunology.

[65]  G. Kochs,et al.  Protective role of interferon-induced Mx GTPases against influenza viruses. , 2009, Revue scientifique et technique.

[66]  Clare L. Bennett,et al.  Clearance of influenza virus from the lung depends on migratory langerin+CD11b− but not plasmacytoid dendritic cells , 2008, The Journal of experimental medicine.

[67]  K. Legge,et al.  The Magnitude of the T Cell Response to a Clinically Significant Dose of Influenza Virus Is Regulated by TRAIL , 2011, The Journal of Immunology.